HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express

Mar 10

Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:

• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.

• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.

Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.

The company will release its FY 2025 financial statements to the public following board approval on the specified date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1148839371"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148839371\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148839371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148839371","market":"us","top_or_hot":-1,"title":"HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.</p>\n<p>• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.</p>\n<p>Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.</p>\n<p>The company will release its FY 2025 financial statements to the public following board approval on the specified date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.</p>\n<p>• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.</p>\n<p>Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.</p>\n<p>The company will release its FY 2025 financial statements to the public following board approval on the specified date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1148839371","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148839371","pubTimestamp":1773132298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes: • Reviewing and approving the Group’s consolidated results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"海西药业(02637)定于2026年3月30日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:\n• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.\n• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.\nBoard composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.\nThe company will release its FY 2025 financial statements to the public following board approval on the specified date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}